中文(繁體)
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Role of Microparticles in Covid-19 Infection

只有註冊用戶可以翻譯文章
登陸註冊
鏈接已保存到剪貼板
狀態尚未招聘
贊助商
University Hospital, Strasbourg, France

關鍵詞

抽象

Among the distinctive features of Covid-19, numerous reports have stressed the importance of vascular damages associated with coagulopathy onset. Microparticles (MPs) shed by apoptotic/stimulated cells are reliable markers of vascular damage released upon pro-inflammatory conditions and behave as active participants in the early steps of clot formation. In addition, MPs carry ACE1 and ACE2, the cell-entry receptor for SARS-Cov2 in the vasculature and up-regulate ACE1 expression in neighbouring endothelial cells. This may contribute to unopposed angiotensin II accumulation which further exacerbate tissue injury and promote both inflammation and thrombosis. The aim of the study is to evaluate the impact of circulating MPs on ACE2 expression, the cell-entry receptor for SARS-Cov2 on endothelial cells.

描述

Circulating MPs will be isolated from Covid-19 patients with lupus anticoagulant, from coronary artery diseases patients and from healthy volunteers without cardiovascular risk factors. Quantification of MPs will be realized by prothrombinase assay. Primary endothelial cells (ECs) from porcine coronary artery or porcine pulmonary artery will be isolated and cultured. ECs will be exposed to circulating MPs. Phenotypical changes (ACE2 expression, cytoadhesins, cytokines, tissue factor expression) of ECs will be examined. Susceptibility of ECs to SARS-COV-2 infection will be determined.

日期

最後驗證: 05/31/2020
首次提交: 06/21/2020
提交的預估入學人數: 06/24/2020
首次發布: 06/25/2020
上次提交的更新: 06/24/2020
最近更新發布: 06/25/2020
實際學習開始日期: 05/31/2020
預計主要完成日期: 10/31/2021
預計完成日期: 10/31/2021

狀況或疾病

COVID-19

干預/治療

Other: Blood sample

-

手臂組

干預/治療
Covid-19 patients
patients with coronary artery disease
healthy volunteers

資格標準

有資格學習的年齡 18 Years 至 18 Years
有資格學習的性別All
取樣方式Non-Probability Sample
接受健康志願者
標準

Inclusion Criteria:

- COVID-19 patients: age > 18 yr

- SARS-COV-2 infection within 12 months and positive lupus anticoagulant

- Patients with cardiovascular risk factors: at least among

- Hypertension, Dyslipidemia, Diabetes mellitus, obesity, smoker, Healthy volunteers

Exclusion Criteria:

- Significant comorbidities (active cancer, auto-immune diseases…)

結果

主要結果指標

1. Western blot measurement of ACE2 receptor expression in porcine cells [Through study completion, an average of 1 year]

加入我們的臉書專頁

科學支持的最完整的草藥數據庫

  • 支持55種語言
  • 科學支持的草藥療法
  • 通過圖像識別草藥
  • 交互式GPS地圖-在位置標記草藥(即將推出)
  • 閱讀與您的搜索相關的科學出版物
  • 通過藥效搜索藥草
  • 組織您的興趣並及時了解新聞研究,臨床試驗和專利

輸入症狀或疾病,並閱讀可能有用的草藥,輸入草藥並查看其所針對的疾病和症狀。
*所有信息均基於已發表的科學研究

Google Play badgeApp Store badge